The aim of this study was to assess the population pharmacokinetics (PopPK) of the novel oral anti-cancer agent E7820. Both a non-linear mixed effects modeling analysis and a non-compartmental analysis (NCA) were performed and results were compared. Data were obtained from a phase I dose escalation study in patients with malignant solid tumors or lymphomas. E7820 was administered daily for 28 days, followed by a washout period of 7 days prior to the start of subsequent cycles. A one compartment model with linear elimination from the central compartment was shown to give adequate fit, while absorption was described using a turnover model. Final population parameter estimates of basic PK parameters obtained with the PopPK method were (RSE): clearance, 6.24 L/h (7.1%), volume of distribution, 66.0 L (8.5%), mean transit time to the absorption compartment, 0.638 h (6.5%). The intake of food prior to dose administration slowed absorption (2.8-fold, RSE 13%) and increased relative bioavailability of E7820 by 36% (RSE 14%), although the effect on Cmax and AUC was not significant. Comparison with the NCA approach showed approximately equal PK parameter estimates and food effect measures, although specific advantages of PopPK included efficiency in use of data and more appropriate assessment of variability.
E7820 Population pharmacokinetics Mixed-effects modeling Non-compartmental analysis Oncology Alpha2-integrin
This is a preview of subscription content, log in to check access.
Funahashi Y et al (2002) Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. Cancer Res 62:6116–6123PubMedGoogle Scholar
Stavri GT et al (1995) Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia. Circulation 92:11–14PubMedGoogle Scholar
Mita MM et al (2005) Pharmacokinetics (PK) and pharmacodynamics (PD) of E7820-an oral sulfonamide with novel, alpha-2 integrin mediated antiangiogenic properties: results of a phase I study. J Clin Oncol 23:3082 Meeting AbstractsGoogle Scholar
Mita MM et al (2006) Phase I study of an anti-angiogenic agent with a novel mechanism of action E7820: safety, pharmacokinetics (PK) and pharmacodynamic (PD) studies in patients (pts) with solid tumors. J Clin Oncol 24:3048 Meeting Abstractsdoi:10.1200/JCO.2004.00.9720CrossRefGoogle Scholar
FDA (1999) Guidance for industry: population pharmacokinetics.Google Scholar
Guo F, Letrent SP, Sharma A (2007) Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors. Cancer Chemother Pharmacol 60:799–809 doi:10.1007/s00280-007-0427-6PubMedCrossRefGoogle Scholar
van Kesteren C et al (2002) Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide). Br J Clin Pharmacol 54:463–471 doi:10.1046/j.1365-2125.2002.01684.xPubMedCrossRefGoogle Scholar
Savic RM, Jonker DM, Kerbusch T, Karlsson MO (2007) Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 34(5):711–726 (Oct)PubMedCrossRefGoogle Scholar